Moderna Refocuses On Rare Diseases As New Leadership Shapes Pipeline [Yahoo! Finance]
Immunocore Holdings plc - American Depositary Shares (IMCR)
Company Research
Source: Yahoo! Finance
Moderna (NasdaqGS:MRNA) announced a collaboration with Recordati to develop and commercialize mRNA-3927 for propionic acidemia, a rare genetic metabolic disorder. The company is also reshaping its leadership team, appointing David Berman as Chief Development Officer and confirming the departure of Chief Medical Officer Jacqueline Miller. These announcements focus attention on Moderna's push into rare diseases alongside leadership changes that may influence its development priorities beyond COVID-19 vaccines. For you as an investor, this combination of a new partnership and senior hires provides a clearer picture of where Moderna plans to focus next. The collaboration around mRNA-3927 extends its mRNA platform into rare metabolic conditions, while the leadership shift adds more oncology and immunotherapy experience alongside its infectious disease work. These developments do not indicate how Moderna will perform, but they do provide new information about the company's directio
Show less
Read more
Impact Snapshot
Event Time:
IMCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMCR alerts
High impacting Immunocore Holdings plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IMCR
News
- VectorY Therapeutics Appoints Kevin Pojasek, Ph.D., to Board of DirectorsBusiness Wire
- Immunocore (NASDAQ:IMCR) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.MarketBeat
- Levicept Announces the Appointment of James Sandy as Chief Development Officer [Yahoo! Finance]Yahoo! Finance
- Levicept Announces the Appointment of James Sandy as Chief Development OfficerGlobeNewswire
- Assessing Immunocore Holdings (IMCR) Valuation After Recent Share Price Volatility [Yahoo! Finance]Yahoo! Finance
IMCR
Earnings
- 11/6/25 - Beat
IMCR
Sec Filings
- 1/30/26 - Form 8-K
- 1/9/26 - Form 8-K
- 12/8/25 - Form 4
- IMCR's page on the SEC website